Axovant Gene Therapies Ltd.
(NASDAQ : AXGT)

( )
AXGT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.69%183.171.3%$509.31m
CELGCelgene Corporation
-0.84%92.411.3%$442.42m
ARRYArray BioPharma Inc.
-0.20%46.128.1%$426.45m
GILDGilead Sciences, Inc.
-2.63%66.680.9%$400.32m
BIIBBiogen Inc.
-0.92%238.071.3%$377.86m
ILMNIllumina, Inc.
-0.48%356.373.5%$303.03m
REGNRegeneron Pharmaceuticals, Inc.
-2.50%305.082.6%$243.93m
VRTXVertex Pharmaceuticals Incorporated
-1.38%177.661.9%$210.42m
ALXNAlexion Pharmaceuticals, Inc.
0.15%125.342.0%$206.43m
EXASExact Sciences Corporation
1.20%112.7924.1%$187.08m
AAgilent Technologies, Inc.
-0.46%72.181.6%$154.39m
BMRNBioMarin Pharmaceutical Inc.
-1.04%82.954.3%$124.74m
SRPTSarepta Therapeutics, Inc.
3.37%128.3414.7%$119.55m
INCYIncyte Corporation
-2.26%85.632.5%$112.69m
MRTXMirati Therapeutics Inc.
-2.09%100.012.5%$104.17m

Company Profile

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.